Pomerantz Law Firm Alerts Investors to Potential Class Action Against ADMA Biologics, Inc.

Investor Alert: Class Action Lawsuit Filed Against ADMA Biologics, Inc.

In recent news, Pomerantz LLP, a law firm renowned for its expertise in class action litigation, has filed a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). This lawsuit comes in response to allegations of potential securities fraud and questionable business practices concerning the company's financial reporting.

The class action specifically invites investors who may have incurred losses during the class period to get in touch with the firm, particularly those who purchased ADMA securities. Affected investors are encouraged to reach out to Danielle Peyton at the firm for more information and to express their intent to join the lawsuit. The deadline to be appointed as Lead Plaintiff is August 10, 2026.

Background on ADMA Biologics

ADMA Biologics is involved in the biopharmaceutical industry, specializing in developing and manufacturing immunoglobulin products from human plasma for the treatment of immune deficiencies. The company has been under scrutiny after a report released by Culper Research on March 24, 2026, raised serious allegations about ADMA's revenue recognition practices. The report suggested that the company's financial growth was overstated, indicating that a de facto channel stuffing scheme and undisclosed related party distributor operations were inflating revenue figures.

Following this report, ADMA's stock plummeted by 16.63%, marking a significant reaction from the market. In the immediate aftermath, Cantor Fitzgerald further downgraded ADMA's stock rating, citing dissatisfaction with the company's response to the allegations. This downgrade resulted in an additional drop in share price, reinforcing investors' fears regarding the company's operations and transparency.

Legal Steps for Investors

For investors who acquired ADMA shares during the period in question, this lawsuit represents a vital opportunity to seek reparations for potential financial losses. Pomerantz LLP has emphasized its readiness to fight against any forms of corporate misconduct and securities fraud practiced by the company and its executives. The law firm has an extensive track record of pioneering securities class actions and has secured significant damages for aggrieved investors over its 85 years of practice.

Investors wishing to join the lawsuit must be proactive. By contacting Pomerantz LLP, they can obtain critical information on how to file their claims and contribute to the collective legal action against ADMA Biologics. The link to accessing the complaint and further documentation can be found on the firm's website.

Conclusion

ADMA Biologics, Inc. finds itself at a pivotal crossroads as it faces serious allegations concerning its financial practices. For investors who feel affected by these developments, taking action through the class action lawsuit could prove essential in recovering losses and holding the company accountable for its actions. Pomerantz LLP continues to advocate for investor rights and remains a reliable ally for those navigating these turbulent waters.

For any inquiries, please reach out directly to Pomerantz LLP or visit their official website for more information.